Testing DLL3 CAR-T cells for some brain tumors
Original title: DLL3 CAR-T Therapy Targeting Brain Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, so it is checking safety first.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a new cell therapy in people whose brain tumor carries a marker called DLL3.
Who this trial is for. This trial is for people with brain tumors that test positive for DLL3. That includes glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary and DIPG or DMG, which are gliomas in the pons or midline of the brain. It tests a treatment called DLL3 CAR-T cell therapy.
Where it stands. The trial has not reported results. It is set up to look at whether this therapy can be given, how safe it is, and how well it works. The team also wants to learn how the anti-DLL3 CAR-T cells work and how long they last in the body. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: For now this is a study, not care your own doctor can offer. If your tumor type is on this list, you could ask your care team whether a DLL3 CAR-T trial is worth looking into. They can tell you if it fits your situation.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Joining one is not a guarantee that you will be helped. It is not a promise of a cure, and some people have side effects.
Source: ClinicalTrials.gov, September 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.